UNSPSC 51150000: Autonomic nervous system drugs

This classification denotes drugs that act on the enteric, parasympathetic, and sympathetic systems taken together.

UNSPSC 51150000 Autonomic nervous system drugs is a Family code with minimal relevant recent state and local procurement activity. The code's abstract name does not align with the concrete work state and local governments are actually buying under it. Among the opportunities posted, only two genuinely solicit pharmaceuticals and medical supplies at the state or local level—Seminole County, Florida's procurement of naloxone and drug deactivation systems (IFB, due July 26, 2023, now expired) and the City of Tucson Fire Department's solicitation for basic and advanced life support pharmaceuticals and supplies (RFP, due June 24, 2026). The Tucson opportunity represents the strongest signal: a multi-group procurement encompassing BLS and ALS pharmaceuticals, controlled substances, diagnostic equipment, vending machine software, and inventory management services, with federal funding through ARPA, HUD, and FTA and multiple compliance overlays including prevailing wage, Davis-Bacon, DBE participation, and Section 3 labor requirements.

Issuing bodies posting under this code are scattered across Florida and Arizona counties and cities; repeat buyers are not evident from the recent record. Geographic activity centers on Florida (Seminole County, Pinellas County with forensic drug standards) and Arizona (Tucson), with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) representing a multi-state pharmaceutical contracting vehicle. The remainder of the opportunities—trade shows, networking events, vendor forums, and grant solicitations for opioid settlement funds—are informational or funding mechanisms rather than product or service procurements, making them tangential to the code's actual buying patterns. The code shows low-volume, episodic procurement activity with no discernible concentration among issuing bodies. Tucson's complex RFP with federal compliance layers and two-year term options and MMCAP's multi-state generic pharmaceutical contract are the only substantive near-term opportunities visible.